In 2016, Cerveau was formed to advance MK-6240 into the mainstream of neurodegenerative disease research. Since then, MK-6240 has become an acknowledged leading imaging biomarker for Tau pathologies, central to AD progression. Cerveau licensed MK-6240 from Merck and committed to establish a broad network of production facilities to support clinical research.
Through the Cerveau Users Group, Pharma companies and leading Acad...
In 2016, Cerveau was formed to advance MK-6240 into the mainstream of neurodegenerative disease research. Since then, MK-6240 has become an acknowledged leading imaging biomarker for Tau pathologies, central to AD progression. Cerveau licensed MK-6240 from Merck and committed to establish a broad network of production facilities to support clinical research.
Through the Cerveau Users Group, Pharma companies and leading Academic centers gain access to MK-6240 for their cutting edge research, share non-competitive data with the entire Users Group and disclose breakthrough science as appropriate.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.